试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-05
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)
编号:NCT04661033登记状态:提前终止企业 / 申办者:Sanofi
药物 / 成分:Isatuximab SAR650984
登记的停止原因(原文):Study discontinuation based on strategic sponsor decision; not driven by any safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-05
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
编号:NCT04826198登记状态:提前终止企业 / 申办者:Gustave Roussy, Cancer Campus, Grand Paris
药物 / 成分:AsiDNA、Niraparib、Olaparib、Rucaparib
登记的停止原因(原文):Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an improved version, and the contract ensuring access to this molecule has expired.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-05
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
编号:NCT04944784登记状态:提前终止企业 / 申办者:Cytokinetics
药物 / 成分:Reldesemtiv、Placebo
登记的停止原因(原文):The DMC recommended the trial be discontinued due to futility following a planned second interim analysis.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-05
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
编号:NCT05049863登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Mycophenolate Mofetil、Allopurinol、Irinotecan
登记的停止原因(原文):Futility
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-05
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
编号:NCT05588440登记状态:提前终止企业 / 申办者:Oncternal Therapeutics, Inc
药物 / 成分:ONCT-808、Bridging Therapy
登记的停止原因(原文):Based on the available clinical data and capital requirements for continued development, the Company has decided to terminate this study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-05
Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure
编号:NCT06080438登记状态:提前终止企业 / 申办者:University of Miami
药物 / 成分:Botulinum toxin
登记的停止原因(原文):Patient recruitment shortage and study coordinator turnover
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-04
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
编号:NCT02550145登记状态:提前终止企业 / 申办者:Tracey McLaughlin
药物 / 成分:Exendin (9-39)、Placebo
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-04
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
编号:NCT04375527登记状态:提前终止企业 / 申办者:Jonsson Comprehensive Cancer Center
药物 / 成分:Binimetinib、Nivolumab、Questionnaire Administration
登记的停止原因(原文):poor enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-04
De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade
编号:NCT04675827登记状态:提前终止企业 / 申办者:Jules Bordet Institute
药物 / 成分:Pertuzumab and tratuzumab fixed dose combination、Trastuzumab emtansine
登记的停止原因(原文):Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evaluate the potential solutions to overcome the issues.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-12-04
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
编号:NCT05511779登记状态:提前终止企业 / 申办者:SymBio Pharmaceuticals
药物 / 成分:Brincidofovir
登记的停止原因(原文):Due to delays in enrollment
查看官方原始记录 ↗